New PET tracer could reveal how lung cancer responds to immunotherapy
NCT ID NCT06439914
First seen Jan 08, 2026 · Last updated Jun 18, 2026 · Updated 32 times
Summary
This early-phase study is testing a special PET imaging agent called [89Zr]Zr-DFO-emapalumab to see if it can detect non-small cell lung cancer lesions and show how well the cancer responds to immunotherapy. Six adults with newly diagnosed lung cancer will receive the imaging agent and undergo PET scans before and about 30 days after starting immunotherapy. The goal is to see if this approach can help doctors better monitor treatment effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.